Pink Sheet Podcast: Mid-Year Drug Approvals, Drug Pricing Hits And Misses, A Plea For More Naloxone, And Gottlieb Goes To Pfizer
Executive Summary
A look back at the implications of the mid-year approval total, developments in drug pricing efforts on and off Capitol Hill, the FDA's plea for generic naloxone, and former commissioner Scott Gottlieb heading to Pfizer's board of directors.